Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOCYTE AMI-3 Phase 3 trial in anterior STEMI undergoing primary PCI
2021-001924-16Phase 3Active
- Sponsor
- Faraday Pharmaceuticals
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sodium iodide in acute ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Faraday Pharmaceuticals. Primary endpoint: Primary composite of cardiovascular mortality or heart failure event through Month 12. Started Nov 2021; status: active.
02
Drugs
Sodium iodide
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on 2021-001924-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001924-16.